Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Secukinumab
Drug ID BADD_D02001
Description Secukinumab (Cosentyx) is a human monoclonal antibody designed for the treatment of uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Secukinumab is an interleukin-17A (IL-17A) inhibitor marketed by Novartis. IL-17 is a group of proinflammatory cytokines released by cells of the immune system and and exist in higher levels in many immune conditions associated with chronic inflammation. By targeting IL-17A, secukinumab has shown excellent efficacy in psoriasis by normalizing skin histology and was approved by the United States Food and Drug Administration on January 21, 2015 to treat adults with moderate-to-severe plaque psoriasis.
Indications and Usage For the treatment of moderate to severe plaque psoriasis in patients that are candidates for systemic therapy or phototherapy.
Marketing Status approved
ATC Code L04AC10
DrugBank ID DB09029
KEGG ID D09967
MeSH ID C555450
PubChem ID Not Available
TTD Drug ID Not Available
NDC Product Code 0078-1070; 0078-1056; 0078-0639
UNII DLG4EML025
Synonyms secukinumab | Cosentyx | AIN 457 | AIN457 | AIN-457
Chemical Information
Molecular Formula Not Available
CAS Registry Number 1229022-83-6
SMILES Not Available
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Conjunctivitis06.04.01.002; 11.01.06.012--
Crohn's disease10.02.01.005; 07.08.01.015--Not Available
Diarrhoea07.02.01.001--
Herpes virus infection11.05.02.008--Not Available
Hypersensitivity10.01.03.003--
Impetigo23.11.02.011; 11.01.12.006--Not Available
Infection11.01.08.002--Not Available
Inflammatory bowel disease07.08.01.016--Not Available
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Neutropenia01.02.03.004--Not Available
Oral candidiasis11.03.03.004; 07.05.07.001--Not Available
Otitis externa11.01.05.003; 04.01.02.001--
Otitis media11.01.05.004; 04.05.01.001--
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Rhinitis22.07.03.006; 11.01.13.004--
Rhinorrhoea22.12.03.021--
Sinusitis22.07.03.007; 11.01.13.005--
Tinea pedis23.11.03.012; 11.03.08.004--Not Available
Tonsillitis22.07.03.008; 11.01.13.006--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urticaria23.04.02.001; 10.01.06.001--
Transaminases increased13.03.04.036--Not Available
Antibody test13.06.03.009--Not Available
Staphylococcal skin infection23.11.02.018; 11.02.05.007--Not Available
Oral herpes07.05.07.002; 11.05.02.005--Not Available
Candida infection11.03.03.021--
The 1th Page    1    Total 1 Pages